Meeting slides
Interactive presentation

Insights Into Pathogenic Mechanisms in SLE

Virginia Pascual, MD
Suggested Readings

American College of Rheumatology (ACR) Annual Meeting Abstracts.

October 19th-24th, 2018. Chicago, Illinios.

Personalized immunomonitoring uncovers molecular networks that stratify lupus patients.

Banchereau R, et al. Cell. 2016;165(3):551-565.

Diagnostic criteria for systemic lupus erythematosus: has the time come?

Bertsias GK, et al. Nat Rev Rheumatol. 2013;9(11):687-694.

Advances in understanding the role of type I interferons in systemic lupus erythematosus.

Crow MK. Curr Opin Rheumatol. 2014;26(5):467-474.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).

Franklyn K, et al. Ann Rheum Dis. 2016;75(9):1615-1621.

Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS [B lymphocyte stimulator], in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus.

Lewis MJ, Jawad AS. Rheumatology (Oxford).

Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study.

Merrill JT, et al. Arthritis Rheumatol. 2018;70(2):266-276.

Connective tissue diseases: remission in SLE—are we there yet?

Morand EF. Nat Rev Rheumatol. 2016;12(12):696-698.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort.

Petri M, Magder LS. Arthritis Rheumatol. May 2018. [Epub ahead of print].

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.

Zimmer R, et al. Ann Rheum Dis. 2013;72(11):1830-1835.

Related activities
Webcast 
1.50 CME/CE

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

Faculty: Richard A. Furie, MD; Eric Morand, MBBS (Hons), FRACP, PhD; Virginia Pascual, MD
Release: 01/07/2019
Expiration: 01/07/2020